Altar M. Munis
PhD, BSc (Hons)
Postdoctoral Research Scientist
Funded by the Wellcome Trust, I am working on the development and optimisation of lentiviral gene therapy for lung diseases. In particular, my current project focuses on the treatment of surfactant protein B deficiency, a fatal autosomal recessive genetic disorder, using Sendai virus F/HN pseudotyped vectors.
Prior to joining the Gene Medicine group, I undertook my doctoral studies in gene therapy and immunology at University College London investigating the properties of phylogenetically distinct vesiculovirus glycoproteins that may have advantages over the prototypical glycoprotein from VSV Indiana strain.
Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom’s first national lockdown
Munis AM. et al, (2021), Scientific Reports, 11
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus.
Downes DJ. et al, (2021), Nat Genet, 53, 1606 - 1615
RNA-Seq Analysis of the Human Surfactant Air-Liquid Interface Culture Reveals Alveolar Type II Cell-like Transcriptome
Munis AM. et al, (2021), Molecular Therapy - Methods & Clinical Development
A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications
Munis AM. et al, (2021), Molecular Therapy - Methods and Clinical Development, 20, 237 - 246
Genome-wide Integration Site Detection Using Cas9 Enriched Amplification-free Long-range Sequencing
HYDE S. et al, (2020), Nucleic Acids Research